Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19608771 | 0.85 | — | — | |
| SCHEMBL950045 | 0.84 | IDH1 (0.39) | DYRK1AHDAC1HDAC6ACHE | |
| SCHEMBL25144874 | 0.82 | DYRK1A (0.36) | DYRK1AHDAC1HDAC6ACHE | |
| SCHEMBL15723799 | 0.82 | DYRK1A (0.36) | DYRK1AHDAC1HDAC6ACHE | |
| SCHEMBL22056656 | 0.81 | DYRK1A (0.35) | DYRK1AHDAC1HDAC6ACHE | |
| SCHEMBL21676107 | 0.78 | DYRK1A (0.33) | DYRK1AHDAC1HDAC6 | |
| SCHEMBL2765749 | 0.78 | — | — | |
| SCHEMBL2956511 | 0.78 | DYRK1A (0.38) | DYRK1A | |
| SCHEMBL20757802 | 0.74 | DYRK1A (0.31) | DYRK1A | |
| SCHEMBL2354268 | 0.74 | KMT2A (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170325459-A1 | BICYCLIC COMPOUNDS AS PEST CONTROL AGENTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-11-16 | — | — | US | disclosed |
| US-20160340322-A1 | SUBSTITUTED TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-11-24 | — | — | US | disclosed |
| EP-3085695-A1 | SUBSTITUTED TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | Nissan Chemical Industries, Ltd. (JP) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015093534-A1 | SUBSTITUTED TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | 日産化学工業株式会社 | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340322-A1 | SUBSTITUTED TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1E, CACNA1I, CACNA1G | DYRK1A 2624/4885HDAC1 905/4885HDAC6 2809/4885 |
| US-20170325459-A1 | BICYCLIC COMPOUNDS AS PEST CONTROL AGENTS | DDT, BCHE, BAK1 | DYRK1A 4348/4885HDAC1 441/4885HDAC6 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.